Literature DB >> 27083147

A combined in vitro approach to improve the prediction of mitochondrial toxicants.

Julie Eakins1, Caroline Bauch1, Heather Woodhouse1, Benjamin Park1, Samantha Bevan1, Clive Dilworth1, Paul Walker2.   

Abstract

Drug induced mitochondrial dysfunction has been implicated in organ toxicity and the withdrawal of drugs or black box warnings limiting their use. The development of highly specific and sensitive in vitro assays in early drug development would assist in detecting compounds which affect mitochondrial function. Here we report the combination of two in vitro assays for the detection of drug induced mitochondrial toxicity. The first assay measures cytotoxicity after 24h incubation of test compound in either glucose or galactose conditioned media (Glu/Gal assay). Compounds with a greater than 3-fold toxicity in galactose media compared to glucose media imply mitochondrial toxicity. The second assay measures mitochondrial respiration, glycolysis and a reserve capacity with mechanistic responses observed within one hour following exposure to test compound. In order to assess these assays a total of 72 known drugs and chemicals were used. Dose-response data was normalised to 100× Cmax giving a specificity, sensitivity and accuracy of 100%, 81% and 92% respectively for this combined approach.
Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Extracellular flux assay; HepG2; In vitro; Mitochondria; Toxicity

Mesh:

Substances:

Year:  2016        PMID: 27083147     DOI: 10.1016/j.tiv.2016.03.016

Source DB:  PubMed          Journal:  Toxicol In Vitro        ISSN: 0887-2333            Impact factor:   3.500


  25 in total

1.  Experimental Evolution of Diverse Strains as a Method for the Determination of Biochemical Mechanisms of Action for Novel Pyrrolizidinone Antibiotics.

Authors:  Kathryn Beabout; Megan D McCurry; Heer Mehta; Akshay A Shah; Kiran Kumar Pulukuri; Stephan Rigol; Yanping Wang; K C Nicolaou; Yousif Shamoo
Journal:  ACS Infect Dis       Date:  2017-09-27       Impact factor: 5.084

2.  Development of a neurotoxicity assay that is tuned to detect mitochondrial toxicants.

Authors:  Johannes Delp; Melina Funke; Franziska Rudolf; Andrea Cediel; Susanne Hougaard Bennekou; Wanda van der Stel; Giada Carta; Paul Jennings; Cosimo Toma; Iain Gardner; Bob van de Water; Anna Forsby; Marcel Leist
Journal:  Arch Toxicol       Date:  2019-06-12       Impact factor: 5.153

Review 3.  Managing the challenge of drug-induced liver injury: a roadmap for the development and deployment of preclinical predictive models.

Authors:  Richard J Weaver; Eric A Blomme; Amy E Chadwick; Ian M Copple; Helga H J Gerets; Christopher E Goldring; Andre Guillouzo; Philip G Hewitt; Magnus Ingelman-Sundberg; Klaus Gjervig Jensen; Satu Juhila; Ursula Klingmüller; Gilles Labbe; Michael J Liguori; Cerys A Lovatt; Paul Morgan; Dean J Naisbitt; Raymond H H Pieters; Jan Snoeys; Bob van de Water; Dominic P Williams; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2019-11-20       Impact factor: 84.694

4.  Mitochondrial Alterations (Inhibition of Mitochondrial Protein Expression, Oxidative Metabolism, and Ultrastructure) Induced by Linezolid and Tedizolid at Clinically Relevant Concentrations in Cultured Human HL-60 Promyelocytes and THP-1 Monocytes.

Authors:  Tamara V Milosevic; Valéry L Payen; Pierre Sonveaux; Giulio G Muccioli; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 5.  Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction.

Authors:  Antonio Segovia-Zafra; Daniel E Di Zeo-Sánchez; Carlos López-Gómez; Zeus Pérez-Valdés; Eduardo García-Fuentes; Raúl J Andrade; M Isabel Lucena; Marina Villanueva-Paz
Journal:  Acta Pharm Sin B       Date:  2021-11-18       Impact factor: 11.413

6.  Acute Maneb Exposure Significantly Alters Both Glycolysis and Mitochondrial Function in Neuroblastoma Cells.

Authors:  Colin C Anderson; Stefanos Aivazidis; Crystal L Kuzyk; Abhilasha Jain; James R Roede
Journal:  Toxicol Sci       Date:  2018-09-01       Impact factor: 4.849

7.  Antiviral Nucleotide Incorporation by Recombinant Human Mitochondrial RNA Polymerase Is Predictive of Increased In Vivo Mitochondrial Toxicity Risk.

Authors:  Martijn Fenaux; Xiaodong Lin; Fumiaki Yokokawa; Zachary Sweeney; Oliver Saunders; Lili Xie; Siew Pheng Lim; Marianne Uteng; Kyoko Uehara; Robert Warne; Wang Gang; Christopher Jones; Satya Yendluri; Helen Gu; Keith Mansfield; Julie Boisclair; Tycho Heimbach; Alexandre Catoire; Kathryn Bracken; Margaret Weaver; Heinz Moser; Weidong Zhong
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

8.  Maneb alters central carbon metabolism and thiol redox status in a toxicant model of Parkinson's disease.

Authors:  Colin C Anderson; John O Marentette; Abhishek K Rauniyar; Kendra M Prutton; Meera Khatri; Chris Matheson; Julie A Reisz; Philip Reigan; Angelo D'Alessandro; James R Roede
Journal:  Free Radic Biol Med       Date:  2020-12-03       Impact factor: 7.376

9.  Synthesis, inhibitory activity and oral dosing formulation of AV5124, the structural analogue of influenza virus endonuclease inhibitor baloxavir.

Authors:  Andrei A Ivashchenko; Oleg D Mitkin; Jeremy C Jones; Alexander V Nikitin; Angela G Koryakova; Ruben N Karapetian; Dmitry V Kravchenko; Stephan V Mochalov; Alexey A Ryakhovskiy; Vladimir Aladinskiy; Irina A Leneva; Irina N Falynskova; Ekaterina A Glubokova; Elena A Govorkova; Alexandre V Ivachtchenko
Journal:  J Antimicrob Chemother       Date:  2021-03-12       Impact factor: 5.790

10.  Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells.

Authors:  Joseph W George; Jane E Mattingly; Nashanthea J Roland; Cassandra M Small; Benjamin G Lamberty; Howard S Fox; Kelly L Stauch
Journal:  Front Immunol       Date:  2021-05-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.